Role of Pharmacotherapy in Cardiac Ion Channelopathies

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|7|3|358-366

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.7, Iss.3, 2009-01, pp. : 358-366

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The genetic and clinical features of cardiac channelopathies

By Roberts Jason D   Gollob Michael H  

Future Cardiology, Vol. 6, Iss. 4, 2010-07 ,pp. : 491-506

Future Medicine

Access to resources Recommend Favorite

Pharmacotherapy of the Ion Transport Defect in Cystic Fibrosis: Role of Purinergic Receptor Agonists and Other Potential Therapeutics

By Kunzelmann K.   Mall M.  

American Journal of Respiratory Medicine, Vol. 2, Iss. 4, 2003-01 ,pp. : 299-309

Adis International

Access to resources Recommend Favorite

The Current Role of Liraglutide in the Pharmacotherapy of Obesity

By  

Current Vascular Pharmacology, Vol. 14, Iss. 2, 2016-03 ,pp. : 201-207

Bentham Science Publishers

Access to resources Recommend Favorite

High-Throughput Screening Strategies for Cardiac Ion Channels

By Numann R.   Negulescu P.A.  

Trends in Cardiovascular Medicine, Vol. 11, Iss. 2, 2001-02 ,pp. : 54-59

Elsevier

Access to resources Recommend Favorite

Cardiac Mechanosensitivity and Stretch-Activated Ion Channels

By Bett G.C.L.   Sachs F.  

Trends in Cardiovascular Medicine, Vol. 7, Iss. 1, 1997-01 ,pp. : 4-8

Elsevier

Access to resources Recommend Favorite